Efficacy and safety of thrombolytic therapy in pulmonary embolism: Meta-analysis of randomized controlled trials;Eficacia y seguridad del tratamiento trombolítico en la tromboembolia pulmonar: Metaanálisis de ensayos controlados y aleatorizados

Medicina Clinica

Volumn 112, Issue 18, 1999, Pages 685-689

  Serra Prat, Mateu ^a,b   Jovell, Albert J ^a   Aymerich, Marta ^a  

^a Agenda d'Avaluacio de Tecn Medica ^*  (Spain)

^b Catalan Agency for Health Technology Assessment and Research   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; UROKINASE;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECURRENCE RISK; TREATMENT OUTCOME;

FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; PULMONARY EMBOLISM; SAFETY; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033594809     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B et al. A population-based perspective of the hospital incidente and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933-938.
2. Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ. Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med 1982; 73: 822-826.
3. Rubinstein I, Murray D, Hoffstein V. Fatal pulmonary embolism in hospitalized patients. Arch Intern Med 1988; 148: 1.425-1.426.
4. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An International Multicentre Trial. Lancet 1975; 2: 45-51.
5. Barrit DW, Jordon SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1: 1.309.
6. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108 (Supl); 312-334.
7. Hommes DW, Bura A, Mazzolai L, Büller HR, Cate JWT. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med 1992; 116: 279-284.
8. Porter JM, Taylor LM. Current status of thrombolytic therapy. J Vasc Surg 1985; 2: 239-249.
9. Goldhaber SZ. Tissue plasminogen activator in acute pulmonary embolism. Chest 1989; 95 (Supl): 282-289.
10. Levine MN, Goldhaber SZ, Gore JM, Hirsh J, Califf RM. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1995; 108 (Supl): 291-301.
11. ISIS-2 [Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
12. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994; 343: 311-322.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
14. Urokinase Pulmonary Embolism Trial Group. Urokinase pulmonary embolism trial. Phase 1 results. A cooperative study. JAMA 1970; 214: 2.163-2.172.
15. Tibbutt DA, Davies JA, Anderson JA, Fletcher EWL, Hamill J, Holt JM et al. Comparison by controled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J 1974; 1: 343-347.
16. Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203: 465-470.
17. Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988; 54: 162-173.
18. PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest 1990; 97: 528-533.
19. Levine M, Hirsh J, Weitz J, Cruickshank M, Meemeh J, Turpie AG et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1.473-1.479.
20. Dalla-Volta S, Palla A, Santolocandro A, Giuntini C, Pengo V, Visioli O et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator italian multicenter study, 2. J Am Coll Cardiol 1992; 20: 520-526.
21. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-511.
22. Miller GAH, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J 1971; 2: 681-684.
23. Sharma GVRK, Burleson VA, Sasahara A. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303: 842-845.
24. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health measures. Statistics and strategies for evaluation. Control Clin Trials 1991; 12 (Supl): 142-158.
25. Anderson DR, Levine NN. Thrombolytic therapy for the treatment of acute pulmonary embolism. Can Med Assoc J 1992; 146: 1.317-1.324.
26. Kessler CM. Modern treatment of pulmonary embolism. Lung 1990; 168 (Supl): 841-848.
27. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Am Coll Physicians 1987; 107; 224-233.
28. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 1995; 333: 1.581-1.587.
29. Goldhaber SZ. Thrombolytic therapy for venous tromboembolism. Baillière's Clin Haematol 1990; 3: 693-704.
30. Gotzsche PC, Liberati A, Torri V, Rossetti L. Beware of surrogate outcome measures. Int J Technol Assess Health Care 1996; 12: 238-246.
31. Thacker SB. Meta-analysis. A quantitative approach to research integration. JAMA 1988; 259: 1.685-1.689.
32. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analysis of randomized controlled trials. N Engl J Med 1987; 316: 450-455.
33. Chan SS, Sacks HS, Chalmers TC. The epidemiology of unpublished randomized control trials [resumen], Clin Res 1982; 30: 234.